Condition: Oesophageal Squamous Cell Carcinoma · Sponsor: Merck Sharp & Dohme LLC
The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goal of this trial is to learn how many participants who receive I-DXd have the cancer respond, which means the cancer gets smaller or goes away.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| UPMC Hillman Cancer Center ( Site 3904) | Pittsburgh, Pennsylvania, United States | Recruiting |
| Liga Norte Riograndense Contra o Cancer ( Site 3301) | Natal, Rio Grande do Norte, Brazil | Recruiting |
| Beijing Cancer Hospital ( Site 2500) | Beijing, Beijing Municipality, China | Recruiting |
| Masarykuv onkologicky ustav ( Site 4000) | Brno, Brno-mesto, Czechia | Recruiting |
| Aichi Cancer Center ( Site 2702) | Nagoya, Aichi-ken, Japan | Recruiting |
| Kanagawa Cancer Center ( Site 2701) | Yokohama, Kanagawa, Japan | Recruiting |
| National Cancer Center Hospital ( Site 2700) | Chūō, Tokyo, Japan | Recruiting |
| Oslo universitetssykehus, Radiumhospitalet ( Site 3501) | Oslo, Norway | Recruiting |
| National Cancer Center ( Site 2902) | Goyang-si, Kyonggi-do, South Korea | Recruiting |
| Asan Medical Center ( Site 2901) | Seoul, South Korea | Recruiting |
| Samsung Medical Center ( Site 2900) | Seoul, South Korea | Recruiting |
| Kantonsspital Graubünden-Medizin ( Site 3700) | Chur, Kanton Graubünden, Switzerland | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07405151